FindTrial
Sign In

Short-term Effects and Safety of an acute increase of intraocular pressure on Corneal Endothelial Cells

Short-term Effects and Safety of an acute increase of intraocular pressure after Intravitreal Bevacizumab injection on Corneal Endothelial Cells

Status
Recruiting
Phases
Unknown
Study type
Observational
Source
CRIS
Registry ID
KCT0002645
Enrollment
50
Registered
2018-01-09
Start date
2018-01-01
Completion date
Unknown
Last updated
2019-03-11

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

None listed

Interventions

None listed

Sponsors

Dankook Univeristy Hospital
Lead Sponsor

Eligibility

Sex/Gender
All

Inclusion criteria

Inclusion criteria: Patients with macular edema or macular degeneration who are scheduled to undergo intravitreal bevacizumab injection. Causes of macular edema: diabetic macular edema, retinal vein occlusion (center, branch), central serous choroidopathy, etc.

Exclusion criteria

Exclusion criteria: Patients were excluded if they had any ocular disease, previous any intravitreal injection, use of topical eyedrops for lowering IOP, or any ocular surgery history except cataract surgery that had no complication like phacoemulsification and posterior chamber lens implantation (PE&PCL).

Design outcomes

Primary

MeasureTime frame
Intraocular pressure;Central corneal thickness;Corneal endothelial cell evaluations (coefficient of variation, hexagonality, cell density)—

Secondary

MeasureTime frame
Ages, Surgical history (Cataract surgery), Presence or absence of diabetes—

Countries

Korea, Republic of

Contacts

Public ContactJIWOONG PARK

Dankook Univeristy Hospital

pjiwoong@hanmail.net+82-41-550-6490

Outcome results

None listed

Source: CRIS (via WHO ICTRP) · Data processed: Mar 7, 2026